Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2021-08, Vol.32 (8), p.994-1004
Hauptverfasser:	Miles, D., Gligorov, J., Cameron, D., Xu, B., Semiglazov, V., Reinisch, M., Patre, M., Morales, L., Patel, S.L., Barata, T., Shao, Z., Wang, X., Geng, C., Yan, X., Tong, Z., Sun, T., Yang, J., Liu, Q., Zhang, S., De Laurentiis, M., Santoro, A., Colleoni, M., Cortesi, L., Placido, S., Ferrau, F., Del Mastro, L., Tonini, G., Montemurro, F., Bianchi, G., Prete, S., Allegrini, G., Naso, G., Vici, P., Loirat, D., Tredan, O., Timar David, M., Dohollou, N., Spano, J.-P., Mansi, L., Andrade, L., Damian, F., Aleixo, S., Junior, R., Grischke, E.-M., Harbeck, N., Peters, U., Fischer, D., Forstbauer, H., Warner, E., Bouganim, N., Vandenberg, T., Pavic, M., Robinson, A., Califaretti, N., Alacacioglu, A., Gumus, M., Yalcin, B., Cicin, I., Kose, F., Cubukcu, E., Wardley, A., Gupta, S., Mohapatra, P., Ghadyalpatil, N., Singhal, M., Agarwal, A., Wolf, I., Gal Yam, E., Yerushalmi, R., Peretz, T., Ben Baruch, N., Hamilton, E., Brufsky, A., Wright, G., Graff, S., Ruiz Borrego, M., Merino, L., Guerra Martinez, J., Ohtani, S., Inoue, K., Ito, Y., Niikura, N., Sagara, Y., Yanagita, Y., Kaen, D., Nervo, A., Melichar, B., Sormova, P., Sufliarsky, J., Kakalejcik, M., Belbaraka, R., Errihani, H., Le Than, D., Pham, D., Papandreou, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	advanced breast cancer atezolizumab immune checkpoint inhibitor paclitaxel PD-L1 triple-negative breast cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!